Gregory R. Cox
Keine laufenden Positionen mehr
Profil
Gregory R.
Cox worked as Treasurer & Vice President at Corixa Corp.
from 1995 to 2005.
He then worked as Chief Financial Officer, Treasurer & Executive VP at Dendreon Corp.
from 2005 to 2015.
In 2015, he briefly served as Chief Financial Officer & Treasurer at Dendreon Corp.
Cox received his undergraduate degree from Otterbein College.
Ehemalige bekannte Positionen von Gregory R. Cox
| Unternehmen | Position | Ende |
|---|---|---|
| DENDREON CORPORATION | Finanzdirektor/CFO | 10.06.2015 |
| DENDREON CORPORATION | Finanzdirektor/CFO | 23.02.2015 |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Treasurer | 01.09.2005 |
Ausbildung von Gregory R. Cox
| Otterbein College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
